Multiple myeloma (MM), a cancer of terminally differentiated plasma cells, is the second
most common hematological malignancy. The disease is characterized by the accumulation …

The development of novel therapies for multiple myeloma (MM) depends on a
comprehensive understanding of the events leading to cellular proliferation and survival …

Although the phosphatidylinositide 3-kinase (PI3K)/Akt pathway has been reported to
contribute to the malignant growth of multiple myeloma (MM), the true relevance of Akt …

Multiple myeloma (MM), which is characterized by osteolytic bone lesions, anemia,
hypercalcemia, and renal failure, accounts for approximately 10% of all hematologic …

Introduction: Multiple myeloma (MM) is an incurable plasma cell malignancy, which causes
significant morbidity due to organ damage and bone tissue destruction. In recent years …

Multiple myeloma is the second most hematological malignancy, accounting for more than
10% of all blood cancers and 2% of annual cancer-related deaths due to lack of curable …

The PI3K/Akt/mTOR signal transduction pathway plays a central role in multiple myeloma
(MM) disease progression and development of therapeutic resistance. mTORC1 inhibitors …

Phosphoinositide-3-kinase and protein kinase B (PI3K-AKT) is upregulated in multiple
myeloma (MM). Using a combination of short hairpin RNA (shRNA) lentivirus-mediated …

Developing effective therapies against multiple myeloma (MM) is an unresolved challenge.
Phosphatidylinositol-3-kinase (PI3K) activation may be associated with tumor progression …

The mammalian target of rapamycin (mTOR) is a PI3K-related serine/threonine kinase and
plays a critical role in modulating proliferation, growth, survival, invasion and …